The Federal Trade Commission (FTC) and the Justice Department’s Antitrust Division, in collaboration with the Department of Commerce and the Department of Health and Human Services, are set to host a series of listening sessions aimed at reducing prescription drug prices through enhanced competition. The first session will focus on identifying anticompetitive practices that hinder generic or biosimilar competition.
This initial session is scheduled for Monday, June 30, 2025, at 2 p.m. Eastern Time. While attendance in person is by invitation only, the event will be available for online streaming. Members of the public can submit questions through an online platform.
Practitioners and scholars will provide remarks during this session. The FTC emphasizes its commitment to promoting competition while protecting and educating consumers. They advise that the FTC will never request money, make threats, instruct individuals to transfer money, or promise prizes.
For more information on how competition benefits consumers or to file an antitrust complaint, individuals are encouraged to follow the FTC on social media, subscribe to press releases, and read their blog.
